BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian ...
(PR-inside.com) BioInvent International (STO:BINV) - Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian Cancer (PRROC)" to be presented at ESMO on October 24 The abstract was published today on the ESMO website. …
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


